2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
AssigneePTC Therapeutics, Inc.
InventorsAndrew W. Hinman, Charles R. Holst, Angela Minnella, Paul Mollard, Sean Pintchovski, Jeffrey K. Trimmer, Eric Torrey
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.
Claims30
A method of treating or suppressing an α-synucleinopathy wherein the α-synucleinopathy is Parkinson's Disease comprising administering to a subject in need thereof a therapeutically effective amount of 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione:
- or the hydroquinone form thereof;
- or a solvate or hydrate thereof;
- or
- administering a pharmaceutical composition comprising 1) a therapeutically effective amount of 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione or the hydroquinone form thereof;
- or a solvate or hydrate thereof;
- and 2) a pharmaceutically acceptable solvent, carrier, or excipient.
(canceled)
9-16. (canceled)
A polymorph of an anhydrate of 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, wherein a powder X-ray diffraction pattern for the polymorph comprises characteristic peaks at least at the following angular positions, wherein the angular positions may vary by ±0.2:
- 4.10, 12.12, and 16.14.
22-34. (canceled)
37-42. (canceled)
(canceled)
A method of recrystallizing 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione from a composition, comprising:
- a) contacting the composition with IPA and water such that the resulting ratio of IPA to water is about 75-87% isopropanol (IPA)/25-13% water (v:v), at a temperature of about 40-45° C.;
- b) cooling the mixture to about 32° C.;
- and
- c) filtering the 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione from the mixture.
55-71. (canceled)
A metastable melted amorphous form of 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, having an XRPD plot substantially as shown in FIG. 31.
Dependencies are inferred from the claim text.